SecBot SecBot

PGEN drug pipeline

PRECIGEN, INC. · 1 rated drug
$4.30
−5.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.7%
1-day, median of 4 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially launched (August 2025).

PAPZIMEOS zopapogene imadenovec Updated Nov 9

What to watch

Watch for the pace of PAPZIMEOS revenue growth in upcoming quarterly reports, particularly whether the drug can maintain its 37% sequential growth trajectory against the new competition from Inovio's VOCERYQ, which was approved on October 30, 2026. Also monitor for a potential EMA marketing authorization application decision for European expansion, which could open a new market.

Bull case
  • PAPZIMEOS is the first and only FDA-approved therapy for adult RRP, a rare disease with significant unmet need. It was granted seven-year orphan drug exclusivity through August 2032, providing a long runway of market protection.
  • Commercial launch has been strong: Q3 2026 PAPZIMEOS net revenue was $72.9M, up 37% sequentially, with $151M in launch-to-date revenue. The company achieved positive operating cash flow of $11.9M in Q3, ahead of guidance.
  • Pivotal trial data showed 51% of patients went a year without surgery, compared to 27% for Inovio's competing product VOCERYQ in its own trial, suggesting a potential efficacy advantage.
Bear case
  • Inovio's VOCERYQ (INO-3107) received accelerated FDA approval on October 30, 2026 for the same RRP indication, creating direct competition. PGEN stock fell 26% on that news, and market share erosion is a real risk.
  • PAPZIMEOS is Precigen's only marketed product, creating extreme single-product concentration risk. Any setback in manufacturing, reimbursement, or competition directly threatens the entire company.
  • Director Jeffrey B. Kindler sold $1.38M worth of PGEN shares on August 26, 2026 at $7.44, and other insiders (CCO, COO) also sold shares in August 2026, signaling potential insider caution near the peak.

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Aug 4, 2026PAPZIMEOSOrphan drug designation+4.2%+3.8%
Nov 1, 2025PAPZIMEOSNDA filed+0.5%−5.8%
Nov 1, 2025PAPZIMEOSOrphan drug designation+0.5%−5.8%
Aug 1, 2025PAPZIMEOSApproval+2.9%+4.1%